CSL Seqirus published Phase 3 results for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc), showing superior immune response and safety in adults aged 50 and older. The vaccine combines three proven methods—MF59 adjuvant, cell-based production, and higher dose—to better protect older adults, whose immune systems weaken with age. The study of 7,699 participants across eight countries demonstrated the vaccine's superiority over existing options and persistent immunity throughout the flu season. Regulatory approvals are underway in multiple markets, with phased introductions expected, potentially improving flu prevention strategies for older adults globally.
Pacifica Hotels G.K. has signed a franchise agreement with Marriott International to open a Courtyard by Marriott hotel in Takayama, Gifu, Japan, scheduled for fall 2028. The hotel will feature 207 rooms and suites designed for both business and leis...
LUXEED held a global media test drive event in Wuhu with 15 automotive media and influencers from UAE, Thailand, and Indonesia. Participants evaluated the luxury MPV LLounge and sports model Stormax over a 185-km route combining highways and mountain...
At the 2026 Thermo Fisher Scientific Junior Innovators Challenge, 15-year-old Bailey Quinn Frank won the $25,000 top prize for designing a low-cost environmental DNA sampler to detect airborne bacteria. This device aims to help rural communities moni...
India's plastics industry is projected to grow from USD 49.98 billion in 2027 to USD 68.41 billion by 2032, at a CAGR of 6.48%. Growth is fueled by rising demand in packaging, pharmaceuticals, electric two-wheelers, and construction, alongside polyme...
COMPASS Pathways is progressing with FDA review for its COMP360 treatment, targeting the large, underserved treatment-resistant depression (TRD) market. The company expects to commercially launch COMP360 in the first half of 2027, potentially benefit...
